Analyst consensus expects Q2 2026 revenue of $698.9 million and an EPS loss of $0.07, with the current stock price of $31.59 trending above the average analyst price target of $29.23.
Investors are primarily focused on the company's "strategic pivot" away from compounded GLP-1 medications toward branded alternatives like Wegovy following recent regulatory and legal challenges. This transition previously triggered a surprise loss and gross margin contraction to 65% in Q1, making margin recovery and subscriber retention critical metrics this quarter.
Management's recently raised full-year 2026 revenue guidance of $2.8 billion to $3.0 billion also serves as a high benchmark for assessing the durability of the platform's recurring growth model.